Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @COIPharma
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @COIPharma
-
COI Pharmaceuticals proslijedio/la je Tweet
New speakers just added: Jay Lichter of
@COIPharma/@AvalonVentures Kim Kamdar (@kpk7767) of Domain Associates Kyle Gano of Neurocrine@NancyAHong of@RiverVest https://xconomy.com/xcelerating-life-sciences-san-diego/ …#XconSDpic.twitter.com/58xfkM1RWL
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Looking forward to Thursday's panel discussion at
#UCSDChangemakerWeek COI's president and CEO, Jay Lichter, will be sharing his experiences serving on#nonprofit boards https://twitter.com/RadySchool/status/1219707175238393856 …pic.twitter.com/aHxIQC0jvG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Happy New Year from the COI team and cheers to another great year ahead!
#SanDiego#biotech#biomedicine#innovationpic.twitter.com/5uCPuxQixA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We have so much to celebrate this season. A big thank you to our clients and our supporters – we wish you all the best for the holiday and new year!pic.twitter.com/kEC7zyTxA3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
New from
@WuXi_AppTec: Jay Lichter shares how pursuing science breakthroughs while mentoring new startups has helped build a strong#biotech pipeline in#SanDiego: http://bit.ly/2X8PPw6#drugdiscovery#drugdevelopment#innovationpic.twitter.com/oONi2Nl5Ti
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
COI announces the acquisition of Calporta by Merck for TRPML1 agonists that could treat lysosomal storage and neurodegenerative diseases. http://bit.ly/2QavULR
#biotech#neurodegeneration#drugdiscovery#innovationpic.twitter.com/2dsZJ1kbR9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sitari, the first company formed under the GSK-Avalon venture collaboration and incubated at COI, has been acquired by
@GSK. GSK will obtain Sitari’s transglutaminase 2 small molecule program for#celiacdisease http://bit.ly/2kr57h7#biotech#innovation#SanDiegopic.twitter.com/2HsnR5U4aY
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Good morning from
#SanFran! COI’s President and CEO Jay Lichter talks with@sandiegoscience about#JPM19https://bit.ly/2C7YPaPHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
It’s been a great year for COI startups! Check out these company milestones, funding successes, honors and more https://bit.ly/2GPXYkB
#SanDiego#biotech#innovation#biomedicineHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cheers from the COI team! May your new year be filled with
#innovation and life-improving#science!#SanDiego#biotech#biomedicinepic.twitter.com/29UmXC4QpG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
COI hopes you and your loved ones have a very happy holiday!pic.twitter.com/J5bWctHNd3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our portfolio company
@synthorx has filed a $100 million IPO. Read more from@sandiegoscience https://bit.ly/2B5hDZ9 And here's more background from their May financing: https://bit.ly/2RSYMpD#SanDiego#biotech#synbio#cancerpic.twitter.com/ImChFylKPR
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
COI portfolio company Fortis Therapeutics has been awarded two investigational new drug (IND) applications for its lead candidate, FOR46, in metastatic castration-resistant prostate cancer and late-stage multiple myeloma. https://bit.ly/2yTnsHG pic.twitter.com/XIy8KqJTKO
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
That's a wrap on another successful Tour de COI. Thanks to all our awesome colleagues who participated in this year's event.
#Biopharma#WeekendWarriors#Cycling#SanDiego#Biotechpic.twitter.com/fOoJS9Klg8
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hunting for a memorable name for your life science startup? Here are some tips on what to consider and what to avoid. https://bit.ly/2EilhlU
#startups#biotech#pharmaHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congrats to COI portfolio company
@Arista_MD for making the@Forbes list of “highest-rated companies for work-life balance in 2018.” AristaMD made the top 10 for small to mid-sized co.’s and was the only SoCal co. on the list.@RachelSMontanezhttps://bit.ly/2OzhncnHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Fran Senchak, COI's VP of Human Resources and Administration, talks about asking for constructive criticism and how that can help further your career in this month’s
@SanDiegoMag feature article#womeninbiosciences http://www.sandiegomagazine.com/San-Diego-Magazine/September-2018/What-San-Diego-Women-Want/ …pic.twitter.com/wMIEKswmME
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The new edition of
@AHL_Magazine is out - be sure to snag a copy or go online to learn more about how the COI community strives to turn dynamic scientific research into breakthroughs. http://bit.ly/2tQqdXu https://twitter.com/COIPharma/status/1008711685761372160 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
COI Pharmaceuticals proslijedio/la je Tweet
Excellent podcast - explains the founding of
@Synthorx in a super interesting interview with our founder@FloydRomesberg !https://twitter.com/rob_reid/status/1011684911965786119 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.